6csy - Revision history

OCA: Redirecting to 6mxt

OCA — Wed, 14 Nov 2018 07:59:37 GMT

Redirecting to 6mxt

←Older revision		Revision as of 07:59, 14 November 2018
Line 1:		Line 1:
-		+	#REDIRECT [[6mxt]] This PDB entry is obsolete and replaced by 6mxt
-	~~==Crystal structure of human beta2 adrenergic receptor bound to salmeterol and Nb71==~~	+
-	~~<StructureSection load='6csy' size='340' side='right' caption='~~[[~~6csy]], [[Resolution\|resolution]] 2.96Å' scene=''>~~	+
-	~~== Structural highlights ==~~	+
-	~~<table><tr><td colspan='2'>[[6csy~~]] is ~~a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Camelus_glama Camelus glama]~~ and [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6CSY OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6CSY FirstGlance]. <br>	+
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=F9S:1-[4-hydroxy-3-(hydroxymethyl)phenyl]-2-{[6-(4-phenylbutoxy)hexyl]amino}ethan-1-one'>F9S</scene>, <scene name='pdbligand=HTO:HEPTANE-1,2,3-TRIOL'>HTO</scene>, <scene name='pdbligand=MG:MAGNESIUM+ION'>MG</scene>, <scene name='pdbligand=NI:NICKEL+(II)+ION'>NI</scene>, <scene name='pdbligand=OLA:OLEIC+ACID'>OLA</scene>, <scene name='pdbligand=OLC:(2R)-2,3-DIHYDROXYPROPYL+(9Z)-OCTADEC-9-ENOATE'>OLC</scene>, <scene name='pdbligand=P33:3,6,9,12,15,18-HEXAOXAICOSANE-1,20-DIOL'>P33</scene></td></tr>	+
-	~~<tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue\|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=YCM:S-(2-AMINO-2-OXOETHYL)-L-CYSTEINE'>YCM</scene></td></tr>~~	+
-	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">ADRB2, ADRB2R, B2AR ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>	+
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6csy FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6csy OCA], [http://pdbe.org/6csy PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6csy RCSB], [http://www.ebi.ac.uk/pdbsum/6csy PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6csy ProSAT]</span></td></tr>	+
-	~~</table>~~	+
-	~~<div style="background-color:#fffaf0;">~~	+
-	~~== Publication Abstract from PubMed ==~~	+
-	Salmeterol is a partial agonist for the beta2 adrenergic receptor (beta2AR) and the first long-acting beta2AR agonist to be widely used clinically for the treatment of asthma and chronic obstructive pulmonary disease. Salmeterol's safety and mechanism of action have both been controversial. To understand its unusual pharmacological action and partial agonism, we obtained the crystal structure of salmeterol-bound beta2AR in complex with an active-state-stabilizing nanobody. The structure reveals the location of the salmeterol exosite, where sequence differences between beta1AR and beta2AR explain the high receptor-subtype selectivity. A structural comparison with the beta2AR bound to the full agonist epinephrine reveals differences in the hydrogen-bond network involving residues Ser204(5.43) and Asn293(6.55). Mutagenesis and biophysical studies suggested that these interactions lead to a distinct active-state conformation that is responsible for the partial efficacy of G-protein activation and the limited beta-arrestin recruitment for salmeterol.	+
-		+
-	Structural insights into binding specificity, efficacy and bias of a beta2AR partial agonist.,Masureel M, Zou Y, Picard LP, van der Westhuizen E, Mahoney JP, Rodrigues JPGLM, Mildorf TJ, Dror RO, Shaw DE, Bouvier M, Pardon E, Steyaert J, Sunahara RK, Weis WI, Zhang C, Kobilka BK Nat Chem Biol. 2018 Nov;14(11):1059-1066. doi: 10.1038/s41589-018-0145-x. Epub, 2018 Oct 16. PMID:30327561<ref>PMID:30327561</ref>	+
-		+
-	~~From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>~~	+
-	~~</div>~~	+
-	~~<div class="pdbe-citations 6csy" style="background-color:#fffaf0;"></div>~~	+
-	~~== References ==~~	+
-	~~<references/>~~	+
-	~~__TOC__~~	+
-	~~</StructureSection>~~	+
-	~~[[Category: Camelus glama]]~~	+
-	~~[[Category: Human]]~~	+
-	~~[[Category: Bouvier, M]]~~	+
-	~~[[Category: Dror, R O]]~~	+
-	~~[[Category: Kobilka, B K]]~~	+
-	~~[[Category: Mahoney, J]]~~	+
-	~~[[Category: Manglik, A]]~~	+
-	~~[[Category: Masureel, M]]~~	+
-	~~[[Category: Mildorf, T J]]~~	+
-	~~[[Category: Pardon, E]]~~	+
-	~~[[Category: Picard, L]]~~	+
-	~~[[Category: Rodrigues, J]]~~	+
-	~~[[Category: Shaw, D E]]~~	+
-	~~[[Category: Steyaert, J]]~~	+
-	~~[[Category: Sunahara, R K]]~~	+
-	~~[[Category: Weiss, W I]]~~	+
-	~~[[Category: Zhang, C]]~~	+
-	~~[[Category: Zou, Y]]~~	+
-	~~[[Category: Active]]~~	+
-	~~[[Category: Adrenergic receptor]]~~	+
-	~~[[Category: Asthma drug]]~~	+
-	~~[[Category: G protein-coupled receptor]]~~	+
-	~~[[Category: Nanobody]]~~	+
-	~~[[Category: Signaling protein]]~~	+

OCA at 07:12, 31 October 2018

OCA — Wed, 31 Oct 2018 07:12:04 GMT

←Older revision		Revision as of 07:12, 31 October 2018
Line 3:		Line 3:
	<StructureSection load='6csy' size='340' side='right' caption='[[6csy]], [[Resolution\|resolution]] 2.96Å' scene=''>		<StructureSection load='6csy' size='340' side='right' caption='[[6csy]], [[Resolution\|resolution]] 2.96Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[6csy]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6CSY OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6CSY FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[6csy]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Camelus_glama Camelus glama] and [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6CSY OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6CSY FirstGlance]. <br>
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=F9S:1-[4-hydroxy-3-(hydroxymethyl)phenyl]-2-{[6-(4-phenylbutoxy)hexyl]amino}ethan-1-one'>F9S</scene>, <scene name='pdbligand=HTO:HEPTANE-1,2,3-TRIOL'>HTO</scene>, <scene name='pdbligand=MG:MAGNESIUM+ION'>MG</scene>, <scene name='pdbligand=NI:NICKEL+(II)+ION'>NI</scene>, <scene name='pdbligand=OLA:OLEIC+ACID'>OLA</scene>, <scene name='pdbligand=OLC:(2R)-2,3-DIHYDROXYPROPYL+(9Z)-OCTADEC-9-ENOATE'>OLC</scene>, <scene name='pdbligand=P33:3,6,9,12,15,18-HEXAOXAICOSANE-1,20-DIOL'>P33</scene></td></tr>		</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=F9S:1-[4-hydroxy-3-(hydroxymethyl)phenyl]-2-{[6-(4-phenylbutoxy)hexyl]amino}ethan-1-one'>F9S</scene>, <scene name='pdbligand=HTO:HEPTANE-1,2,3-TRIOL'>HTO</scene>, <scene name='pdbligand=MG:MAGNESIUM+ION'>MG</scene>, <scene name='pdbligand=NI:NICKEL+(II)+ION'>NI</scene>, <scene name='pdbligand=OLA:OLEIC+ACID'>OLA</scene>, <scene name='pdbligand=OLC:(2R)-2,3-DIHYDROXYPROPYL+(9Z)-OCTADEC-9-ENOATE'>OLC</scene>, <scene name='pdbligand=P33:3,6,9,12,15,18-HEXAOXAICOSANE-1,20-DIOL'>P33</scene></td></tr>
	<tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue\|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=YCM:S-(2-AMINO-2-OXOETHYL)-L-CYSTEINE'>YCM</scene></td></tr>		<tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue\|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=YCM:S-(2-AMINO-2-OXOETHYL)-L-CYSTEINE'>YCM</scene></td></tr>
		+	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">ADRB2, ADRB2R, B2AR ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6csy FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6csy OCA], [http://pdbe.org/6csy PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6csy RCSB], [http://www.ebi.ac.uk/pdbsum/6csy PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6csy ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6csy FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6csy OCA], [http://pdbe.org/6csy PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6csy RCSB], [http://www.ebi.ac.uk/pdbsum/6csy PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6csy ProSAT]</span></td></tr>
	</table>		</table>
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	Salmeterol is a partial agonist for the beta2 adrenergic receptor (beta2AR) and the first long-acting beta2AR agonist to be widely used clinically for the treatment of asthma and chronic obstructive pulmonary disease. Salmeterol's safety and mechanism of action have both been controversial. To understand its unusual pharmacological action and partial agonism, we obtained the crystal structure of salmeterol-bound beta2AR in complex with an active-state-stabilizing nanobody. The structure reveals the location of the salmeterol exosite, where sequence differences between beta1AR and beta2AR explain the high receptor-subtype selectivity. A structural comparison with the beta2AR bound to the full agonist epinephrine reveals differences in the hydrogen-bond network involving residues Ser204(5.43) and Asn293(6.55). Mutagenesis and biophysical studies suggested that these interactions lead to a distinct active-state conformation that is responsible for the partial efficacy of G-protein activation and the limited beta-arrestin recruitment for salmeterol.
		+
		+	Structural insights into binding specificity, efficacy and bias of a beta2AR partial agonist.,Masureel M, Zou Y, Picard LP, van der Westhuizen E, Mahoney JP, Rodrigues JPGLM, Mildorf TJ, Dror RO, Shaw DE, Bouvier M, Pardon E, Steyaert J, Sunahara RK, Weis WI, Zhang C, Kobilka BK Nat Chem Biol. 2018 Nov;14(11):1059-1066. doi: 10.1038/s41589-018-0145-x. Epub, 2018 Oct 16. PMID:30327561<ref>PMID:30327561</ref>
		+
		+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
		+	</div>
		+	<div class="pdbe-citations 6csy" style="background-color:#fffaf0;"></div>
		+	== References ==
		+	<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Camelus glama]]
		+	[[Category: Human]]
	[[Category: Bouvier, M]]		[[Category: Bouvier, M]]
	[[Category: Dror, R O]]		[[Category: Dror, R O]]

OCA at 05:52, 24 October 2018

OCA — Wed, 24 Oct 2018 05:52:08 GMT

←Older revision		Revision as of 05:52, 24 October 2018
Line 1:		Line 1:
-	'''Unreleased structure'''

-	~~The entry~~ 6csy ~~is ON HOLD until Paper Publication~~	+	==Crystal structure of human beta2 adrenergic receptor bound to salmeterol and Nb71==
-		+	<StructureSection load='6csy' size='340' side='right' caption='[[6csy]], [[Resolution\|resolution]] 2.96Å' scene=''>
-	~~Authors~~: ~~Zou, Y~~.~~, Masureel, M~~., ~~Picard~~, L., ~~Mahoney~~, J., ~~Manglik~~, A., ~~Rodrigues~~, J., ~~Mildorf~~, ~~T.J.~~, ~~Bouvier~~, M., ~~Dror~~, R.O.~~, Shaw, D~~.E., ~~Pardon, E~~., ~~Steyaert, J~~., ~~Sunahara, R~~.K., ~~Weiss, W~~.I.~~, Zhang, C~~., ~~Kobilka, B~~.K.	+	== Structural highlights ==
-		+	<table><tr><td colspan='2'>[[6csy]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6CSY OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6CSY FirstGlance]. <br>
-	~~Description: Crystal structure of human beta2 adrenergic receptor bound to salmeterol and Nb71~~	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=F9S:1-[4-hydroxy-3-(hydroxymethyl)phenyl]-2-{[6-(4-phenylbutoxy)hexyl]amino}ethan-1-one'>F9S</scene>, <scene name='pdbligand=HTO:HEPTANE-1,2,3-TRIOL'>HTO</scene>, <scene name='pdbligand=MG:MAGNESIUM+ION'>MG</scene>, <scene name='pdbligand=NI:NICKEL+(II)+ION'>NI</scene>, <scene name='pdbligand=OLA:OLEIC+ACID'>OLA</scene>, <scene name='pdbligand=OLC:(2R)-2,3-DIHYDROXYPROPYL+(9Z)-OCTADEC-9-ENOATE'>OLC</scene>, <scene name='pdbligand=P33:3,6,9,12,15,18-HEXAOXAICOSANE-1,20-DIOL'>P33</scene></td></tr>
-	~~[[Category: Unreleased Structures]]~~	+	<tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue\|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=YCM:S-(2-AMINO-2-OXOETHYL)-L-CYSTEINE'>YCM</scene></td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6csy FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6csy OCA], [http://pdbe.org/6csy PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6csy RCSB], [http://www.ebi.ac.uk/pdbsum/6csy PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6csy ProSAT]</span></td></tr>
		+	</table>
		+	__TOC__
		+	</StructureSection>
	[[Category: Bouvier, M]]		[[Category: Bouvier, M]]
		+	[[Category: Dror, R O]]
		+	[[Category: Kobilka, B K]]
		+	[[Category: Mahoney, J]]
		+	[[Category: Manglik, A]]
	[[Category: Masureel, M]]		[[Category: Masureel, M]]
-	[[Category: ~~Weiss~~, ~~W.I~~]]	+	[[Category: Mildorf, T J]]
-	[[Category: ~~Steyaert~~, J]]	+	[[Category: Pardon, E]]
	[[Category: Picard, L]]		[[Category: Picard, L]]
-	[[Category: Manglik, A]]
	[[Category: Rodrigues, J]]		[[Category: Rodrigues, J]]
-	[[Category: ~~Mahoney~~, J]]	+	[[Category: Shaw, D E]]
-	[[Category: ~~Pardon~~, E]]	+	[[Category: Steyaert, J]]
-	[[Category: ~~Shaw~~, ~~D.E~~]]	+	[[Category: Sunahara, R K]]
		+	[[Category: Weiss, W I]]
	[[Category: Zhang, C]]		[[Category: Zhang, C]]
-	[[Category: Dror, R.O]]
-	[[Category: Mildorf, T.J]]
	[[Category: Zou, Y]]		[[Category: Zou, Y]]
-	[[Category: ~~Sunahara, R.K~~]]	+	[[Category: Active]]
-	[[Category: ~~Kobilka, B.K~~]]	+	[[Category: Adrenergic receptor]]
		+	[[Category: Asthma drug]]
		+	[[Category: G protein-coupled receptor]]
		+	[[Category: Nanobody]]
		+	[[Category: Signaling protein]]

OCA at 04:01, 25 April 2018

OCA — Wed, 25 Apr 2018 04:01:18 GMT

←Older revision		Revision as of 04:01, 25 April 2018
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 6csy is ON HOLD	+	The entry 6csy is ON HOLD until Paper Publication

	Authors: Zou, Y., Masureel, M., Picard, L., Mahoney, J., Manglik, A., Rodrigues, J., Mildorf, T.J., Bouvier, M., Dror, R.O., Shaw, D.E., Pardon, E., Steyaert, J., Sunahara, R.K., Weiss, W.I., Zhang, C., Kobilka, B.K.		Authors: Zou, Y., Masureel, M., Picard, L., Mahoney, J., Manglik, A., Rodrigues, J., Mildorf, T.J., Bouvier, M., Dror, R.O., Shaw, D.E., Pardon, E., Steyaert, J., Sunahara, R.K., Weiss, W.I., Zhang, C., Kobilka, B.K.

OCA: Protected "6csy" [edit=sysop:move=sysop]

OCA — Wed, 28 Mar 2018 05:22:01 GMT

Protected "6csy" [edit=sysop:move=sysop]

←Older revision

Revision as of 05:22, 28 March 2018

OCA: New page: '''Unreleased structure''' The entry 6csy is ON HOLD Authors: Zou, Y., Masureel, M., Picard, L., Mahoney, J., Manglik, A., Rodrigues, J., Mildorf, T.J., Bouvier, M., Dror, R.O., Shaw, D...

OCA — Wed, 28 Mar 2018 05:22:00 GMT

New page: '''Unreleased structure''' The entry 6csy is ON HOLD Authors: Zou, Y., Masureel, M., Picard, L., Mahoney, J., Manglik, A., Rodrigues, J., Mildorf, T.J., Bouvier, M., Dror, R.O., Shaw, D...

New page

'''Unreleased structure'''

The entry 6csy is ON HOLD

Authors: Zou, Y., Masureel, M., Picard, L., Mahoney, J., Manglik, A., Rodrigues, J., Mildorf, T.J., Bouvier, M., Dror, R.O., Shaw, D.E., Pardon, E., Steyaert, J., Sunahara, R.K., Weiss, W.I., Zhang, C., Kobilka, B.K.

Description: Crystal structure of human beta2 adrenergic receptor bound to salmeterol and Nb71
[[Category: Unreleased Structures]]
[[Category: Bouvier, M]]
[[Category: Masureel, M]]
[[Category: Weiss, W.I]]
[[Category: Steyaert, J]]
[[Category: Picard, L]]
[[Category: Manglik, A]]
[[Category: Rodrigues, J]]
[[Category: Mahoney, J]]
[[Category: Pardon, E]]
[[Category: Shaw, D.E]]
[[Category: Zhang, C]]
[[Category: Dror, R.O]]
[[Category: Mildorf, T.J]]
[[Category: Zou, Y]]
[[Category: Sunahara, R.K]]
[[Category: Kobilka, B.K]]